To frame up how the Biotech IPO markets have evolved over the past six years, the author reviews data around the changes to pre-money valuations over time. The trend line is clear: up and to the right
To frame up how the Biotech IPO markets have evolved over the past six years, the author reviews data around the changes to pre-money valuations over time. The trend line is clear: up and to the right